CPA Ranked Top in Innovators of China Anti-cancer Drugs 2017
China Patent Agent (H.K.) Ltd. (CPA) is pleased to report that our firm has been ranked No. 1 in Innovators of China Anti-cancer Drugs 2017 jointly released by Patsnap Pte. Ltd. and Pharmacodia.
"Innovators of China Anti-cancer Drugs" identified entities with leading contribution to innovation in the field of anti-cancer drugs under three categories, namely, enterprises, colleges and research institutes, and IP agencies, benefited from global big data as related to patent filings, grants, and valuation. CPA was placed top on the list of IP agencies, with an innovation capacity calculated on the basis of applications for patent for anti-cancer drugs and grants thereof our firm handled during the year.
Anti-cancer drugs, together with biotech drugs, neurological drugs, anti-infective drugs, and compounds, comprise the top five therapeutic products in R&D of new drugs in China. And the number of anti-cancer drugs in China, according to China Pharmacy Net (zyzhan.com), has exceeded 4,000 in 2016, an increase of about 16% from 2015, far surpassing the average growth of 11.5% of the pharma R&D industry.
In recent years, researches and patent filings related to anti-cancer drugs have been active in China. According to Patsnap's global patent database, cumulative patent applications relating to anti-cancer drugs in China have reached 40,000, with a rapid growth momentum continued to be seen since 2012, and filing of this type of patent applications exceeding 5,000 in both 2015 and 2016.
Patsnap operates innovation intelligence, patent search, and IP analytics software founded in 2007 with offices in Los Angeles, London, Singapore and China, and Pharmacodia is an online platform which provides big data and information services in the pharma R&D field.
